Clinical trials that examine the ADRB2 antagonists propranolol (NCT03152786) and carvedilol (NCT02944201) in primary PCa are ongoing; however, no clinical studies have been reported in CRPC patients. This evidence concerns the gene ADRB2 and posterior cortical atrophy.